List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: Adecto Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of a mucosal RSV vaccine

    SBC: Biomedical Research Models, Inc.            Topic: NIAID

    Abstract Human respiratory syncytial virus RSV is a highly infectious member of the paramyxovirus family causing upper and lower respiratory tract infections RSV is the leading cause of pulmonary disease of the lower respiratory tract bronchiolitis pneumonia and respiratory failure in infants due to virus induced airway damage and complex inflammatory processes and responsible for an estima ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Novel beta lactams as inhibitors of ebola virus infections

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Ebola virus EBOV is a member of the filovirus family that causes severe viral hemorrhagic fever VHF Although infrequent epidemics of EBOV can cause high mortality rates of up to the subsequent medical and social upheaval can be widespread and severe as seen in the recent outbreak in Western Africa which has already caused more than fatalities ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Biopsy Probes with Real time Multi modality Image Guidance for Peripheral Lung Nodules

    SBC: LX Medical            Topic: NCI

    DESCRIPTION provided by applicant Recent technological advances have enabled low dose spiral CT to become an effective tool for lung cancer screening The majority of pulmonary nodules detected on CT however are small and difficult to diagnose While CT guided transthoracic needle biopsy CT TTNB has high diagnostic accuracy to depending on nodule size the risk of complications su ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity

    SBC: Fairbanks Pharmaceuticals Inc            Topic: 200

    DESCRIPTION provided by applicant Both type and type diabetes involve loss of insulin producing pancreatic cells resulting in inadequate insulin secretion to control blood glucose Eventually daily injections of insulin are required to avoid the constellation of pathologies that arise from hyperglycemia While transplantation of cadaveric pancreatic islets that contain cells has been s ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Flowable antimicrobial skin scaffolding matrix that promotes regeneration

    SBC: GEL4MED, INC.            Topic: 300

    DESCRIPTION provided by applicant The goal of this Phase I SBIR proposal is to test the feasibility of an antimicrobial tissue scaffolding hydrogel matrix in eliminating infecting bacteril pathogens and promoting wound regeneration Preventing and treating wound infections and regeneration are becoming less effective due to the rapid rise in Multi drug Resistant Organisms MDRO A recent study by Pad ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. High Speed Multi sensor Light Field Deconvolution Microscopy for Whole Brain Recording of Neuronal Activity

    SBC: Leaflabs, LLC            Topic: 101

    DESCRIPTION provided by applicant Recording all the neural activity in a D volume with millisecond timescale precision is a key goal of the BRAIN initiative Recently in a collaborative project with the Vaziri lab IMP Vienna we adapted the strategy of lightfield microscopy for D volumetric imaging of fluorescent neural calcium responses Prevedel This technology enables computatio ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER'S DISEASE

    SBC: Klogene Therapeutics, Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD is one of the most significant public health problems of the st century with the number of patients in the US estimated to grow from million to million by and an annual cost of care projected to reach $ trillion Current treatments for AD have limited effect for a short duration and only serve to alleviate sympto ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Exploratory Chemistry on a new antibiotic

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: NIAID

    This project studies the structure activity relationship SAR of the newly discovered antibiotic teixobactin with the goal of delivering a candidate that has development advantages over the parent compound Teixobactin is an unusual depsipeptide that is the first member of a novel class of peptidoglycan synthesis inhibitors Teixobactin targets lipid II peptidoglycan precursor and lipid III t ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government